JINGXIN(SZ:002020)2023-10-13 10:26Group 1: Strategic Focus - The company will continue to focus on innovative drugs in the fields of mental health and cardiovascular diseases, specifically targeting conditions such as schizophrenia, Parkinson's disease, depression, and epilepsy [2][3] - The integration of raw materials and formulations is a key strategic direction, with a focus on both self-research and external introduction of new products [2][3] Group 2: Production and Capacity Expansion - The company has over 30 years of experience in the intermediate and raw material pharmaceutical industry, supporting its ability to integrate raw materials and formulations effectively [3] - Recent capacity expansions are aimed at overcoming production bottlenecks across different business segments, with a balanced approach to investment and returns [3] Group 3: Sales and Market Adaptation - A restructuring of the sales organization has been implemented to better align with market trends and the company's business characteristics, which may temporarily impact performance but is expected to lay a foundation for sustainable growth [3] - Sales have shown signs of recovery and are trending positively following the adjustments made earlier in the year [3]